Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 656-668

  Topp, Monique D ^a,b   Hartley, Lynne ^a   Cook, Michele ^a   Heong, Valerie ^a,c,d   Boehm, Emma ^a   McShane, Lauren ^a   Pyman, Jan ^c   McNally, Orla ^c   Ananda, Sumitra ^c   Harrell, Marisol ^e   Etemadmoghadam, Dariush ^d,f   Galletta, Laura ^f   Alsop, Kathryn ^f   Mitchell, Gillian ^f   Fox, Stephen B ^d,f   Kerr, Jeffrey B ^b   Hutt, Karla J ^b,g   Kaufmann, Scott H ^h   Australian Ovarian Cancer Study, ^f,i,j,k   Swisher, Elizabeth M ^e   Bowtell, David D ^d,f   Wakefield, Matthew J ^a,d   Scott, Clare L ^a,c,d   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF WASHINGTON   (United States)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h MAYO CLINIC CANCER CENTER   (United States)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j WESTMEAD HOSPITAL   (Australia)

^k QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

more..

Author keywords

BRCA1; BRCA2; DNA repair; Platinum; Serous ovarian cancer; Xenograft

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLIN E; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; MISMATCH REPAIR PROTEIN PMS2; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TRANSCRIPTION FACTOR PAX8; WT1 PROTEIN; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPAIR; FAMILY HISTORY; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENE OVEREXPRESSION; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MISSENSE MUTATION; MOUSE; NONHUMAN; ONCOGENE; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DNA METHYLATION; DRUG EFFECTS; GENETICS; MUTATION; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; SCID MOUSE; XENOGRAFT;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; DNA METHYLATION; FEMALE; HUMANS; MICE; MICE, SCID; MUTATION; OVARIAN NEOPLASMS; OVARY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84899475102     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.01.008     Document Type: Article

References (33)

1. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., Stewart C., Fereday S., Caldas C., Defazio A., et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J.Pathol. 2010, 221:49-56.
2. Alsop K., Fereday S., Meldrum C., Defazio A., Emmanuel C., George J., Dobrovic A., Birrer M.J., Webb P.M., Stewart C., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J.Clin. Oncol. 2012, 30(21). 2654-63.
3. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
4. Barber L.J., Sandhu S., Chen L., Campbell J., Kozarewa I., Fenwick K., Assiotis I., Rodrigues D.N., Reis Filho J.S., Moreno V., et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J.Pathol. 2013, 229:422-429.
5. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
6. Bookman M.A. Update of randomized trials in first-line treatment. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol./ESMO 2011, 22(Suppl. 8):viii52-viii60.
7. Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., Colombo N., Fowler J.M., Argenta P.A., De Geest K., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J.Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009, 27:1419-1425.
8. Cragg M.S., Harris C., Strasser A., Scott C.L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 2009, 9:321-326.
9. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat. Rev. Cancer 2004, 4:769-780.
10. Domcke S., Sinha R., Levine D.A., Sander C., Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 2013, 4:2126.
11. Easton D.F., Deffenbaugh A.M., Pruss D., Frye C., Wenstrup R.J., Allen-Brady K., Tavtigian S.V., Monteiro A.N., Iversen E.S., Couch F.J., et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet. 2007, 81:873-883.
12. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
13. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J.Natl. Cancer Inst. 2000, 92:564-569.
14. Etemadmoghadam D., George J., Cowin P.A., Cullinane C., Kansara M., Gorringe K.L., Smyth G.K., Bowtell D.D. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PloS One 2010, 5:e15498.
15. Faratian D., Zweemer A.J., Nagumo Y., Sims A.H., Muir M., Dodds M., Mullen P., Um I., Kay C., Hasmann M., et al. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin. Cancer Res. An Off. J. Am. Assoc. Cancer Res. 2011, 17:4451-4461.
16. Frampton G.M., Fichtenholtz A., Otto G.A., Wang K., Downing S.R., He J., Schnall-Levin M., White J., Sanford E.M., An P., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 2013, 31:1023-1031.
17. Helland A., Anglesio M.S., George J., Cowin P.A., Johnstone C.N., House C.M., Sheppard K.E., Etemadmoghadam D., Melnyk N., Rustgi A.K., et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PloS One 2011, 6:e18064.
18. Kaye S.B., Lubinski J., Matulonis U., Ang J.E., Gourley C., Karlan B.Y., Amnon A., Bell-McGuinn K.M., Chen L.M., Friedlander M., et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J.Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012, 30:372-379.
19. Kortmann U., McAlpine J.N., Xue H., Guan J., Ha G., Tully S., Shafait S., Lau A., Cranston A.N., O'Connor M.J., et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011, 17:783-791.
20. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N.Engl. J. Med. 2012, 366:1382-1392.
21. Lee C.H., Xue H., Sutcliffe M., Gout P.W., Huntsman D.G., Miller D.M., Gilks C.B., Wang Y.Z. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol. Oncol. 2005, 96:48-55.
22. Narita M., Nunez S., Heard E., Narita M., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
23. Norquist B., Wurz K.A., Pennil C.C., Garcia R., Gross J., Sakai W., Karlan B.Y., Taniguchi T., Swisher E.M. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J.Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011, 29:3008-3015.
24. Press J.Z., Kenyon J.A., Xue H., Miller M.A., De Luca A., Miller D.M., Huntsman D.G., Gilks C.B., McAlpine J.N., Wang Y.Z. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol. Oncol. 2008, 110:256-264.
25. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
26. Roby K.F., Taylor C.C., Sweetwood J.P., Cheng Y., Pace J.L., Tawfik O., Persons D.L., Smith P.G., Terranova P.F. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000, 21:585-591.
27. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
28. Sims A.H., Zweemer A.J., Nagumo Y., Faratian D., Muir M., Dodds M., Um I., Kay C., Hasmann M., Harrison D.J., et al. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br. J. Cancer 2012, 106:1779-1789.
29. Stewart J.M., Shaw P.A., Gedye C., Bernardini M.Q., Neel B.G., Ailles L.E. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:6468-6473.
30. Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., et al. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol. Oncol. 2013, 7:567-579.
31. TCGA Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
32. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J.D., Coukos G., Crum C.C., Drapkin R., Etemadmoghadam D., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11:719-725.
33. Walsh T., Casadei S., Lee M.K., Pennil C.C., Nord A.S., Thornton A.M., Roeb W., Agnew K.J., Stray S.M., Wickramanayake A., et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(44). 18032-7.